ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years
Gemma Rossi
Matched on ORCID iD 0000-0003-4071-8247; OpenAlex author ID A5051945781. Sources: OpenAlex.
Their work
- Papers
- 9
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 32
2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 9
- Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. Co-author DOI 10.1002/ueg2.70179↗
- Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
- Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
- Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
- EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control stud… Co-author DOI 10.4103/eus-d-21-00200↗
- Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
- Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomi… Co-author DOI 10.3390/cancers13184512↗
- Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Co-author DOI 10.1055/a-1221-9879↗
- RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Co-author DOI 10.3390/cells9122561↗
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michele Reni · 9 shared papers, 2020–2026 · strength 1.27
- Paper Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. DOI 10.1002/ueg2.70179↗
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Maria Chiara Petrone · 8 shared papers, 2020–2026 · strength 1.15
- Paper Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. DOI 10.1002/ueg2.70179↗
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Massimo Falconi · 8 shared papers, 2020–2026 · strength 1.15
- Paper Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. DOI 10.1002/ueg2.70179↗
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Paolo Giorgio Arcidiacono · 8 shared papers, 2020–2026 · strength 1.15
- Paper Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. DOI 10.1002/ueg2.70179↗
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Gabriele Capurso · 7 shared papers, 2020–2026 · strength 1.01
- Paper Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. DOI 10.1002/ueg2.70179↗
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DOI 10.1002/deo2.152↗
- Lívia Archibugi · 5 shared papers, 2020–2026 · strength 0.77
- Paper Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. DOI 10.1002/ueg2.70179↗
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DOI 10.1002/deo2.152↗
- Sabrina Gloria Giulia Testoni · 6 shared papers, 2020–2023 · strength 0.69
- Paper Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DOI 10.1002/deo2.152↗
- Paper EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic du… DOI 10.4103/eus-d-21-00200↗
- Paper Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. DOI 10.1007/s00280-020-04190-1↗
- Claudio Doglioni · 5 shared papers, 2020–2023 · strength 0.60
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Paper Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DOI 10.1002/deo2.152↗
- Paper Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. DOI 10.1007/s00280-020-04190-1↗
- Francesco DE COBELLI · 4 shared papers, 2020–2023 · strength 0.47
- Paper Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DOI 10.1002/deo2.152↗
- Paper EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic du… DOI 10.4103/eus-d-21-00200↗
- Paper Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectab… DOI 10.3390/cancers13184512↗
- Ruggero Ponz de Leon Pisani · 2 shared papers, 2025–2026 · strength 0.44
- Marina Macchini · 3 shared papers, 2021–2025 · strength 0.44
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Paper Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. DOI 10.1007/s00280-020-04190-1↗
- Giulia Orsi · 3 shared papers, 2021–2025 · strength 0.44
- Paper Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. DOI 10.1016/j.dld.2025.03.009↗
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Paper Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. DOI 10.1007/s00280-020-04190-1↗
- Gianpaolo Balzano · 3 shared papers, 2021–2023 · strength 0.38
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Paper EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic du… DOI 10.4103/eus-d-21-00200↗
- Paper Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectab… DOI 10.3390/cancers13184512↗
- Emanuel Della‐Torre · 3 shared papers, 2020–2022 · strength 0.33
- Paper EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic du… DOI 10.4103/eus-d-21-00200↗
- Paper Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectab… DOI 10.3390/cancers13184512↗
- Paper Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of loc… DOI 10.1055/a-1221-9879↗
- Matteo Tacelli · 2 shared papers, 2023–2025 · strength 0.32
- Giuseppe Vanella · 2 shared papers, 2023–2025 · strength 0.32
- Domenico Tamburrino · 2 shared papers, 2021–2025 · strength 0.29
- Marco Schiavo Lena · 2 shared papers, 2023 · strength 0.28
- Giulio Belfiori · 2 shared papers, 2021–2023 · strength 0.25
- Miriam Redegalli · 2 shared papers, 2020–2023 · strength 0.24
- Paper Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Sampl… DOI 10.1016/j.cgh.2022.10.014↗
- Paper RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of … DOI 10.3390/cells9122561↗
- Giovanni Guarneri · 1 shared paper, 2025 · strength 0.18
- Gaetano Lauri · 1 shared paper, 2025 · strength 0.18
- Maria Giulia Cangi · 1 shared paper, 2023 · strength 0.14
- Diego Palumbo · 1 shared paper, 2023 · strength 0.14
- Stefano Crippa · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.